Document Information

Title: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Source: https://storage.googleapis.com/polarys-documents/uploads/b87e91b9-caff-4606-aa4e-ef37814702ca.txt

Content Type: press_release

Word Count: 2757

Applied Auto Tags
Auto Tag Description Extracted Value Confidence Applied Actions
Executives No description Stephanie Fradette N/A N/A
Communication Type No description Press Release N/A N/A
CEO No description The most prominent company mentioned in the document is Biogen Inc. The document was published on June 18, 2025., According to multiple sources, Christopher Viehbacher (also referred to as Chris Viehbacher) was the President and Chief Executive Officer of Biogen Inc. in June 2025. He joined Biogen in November 2022. Christopher Viehbacher was discussed in articles published in February, March, and May 2025 as the CEO of Biogen. Additionally, a filing from June 2, 2025, also confirms his role as CEO., Christopher Viehbacher N/A N/A
Company No description Biogen N/A N/A
CEO No description Christopher Viehbacher N/A N/A
About Auto Tags
Automatic Extraction

Auto tags use AI to automatically extract specific information from this document based on predefined rules.

Re-apply Tags

You can re-apply auto tags to get updated extractions if the auto tag rules have been modified.

Remove Tags

Remove individual auto tags or use "Remove All Tags" to bulk remove all applied tags at once.